These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34904813)

  • 21. Therapeutic opportunities within the DNA damage response.
    Pearl LH; Schierz AC; Ward SE; Al-Lazikani B; Pearl FM
    Nat Rev Cancer; 2015 Mar; 15(3):166-80. PubMed ID: 25709118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the DNA damage response in oncology: past, present and future perspectives.
    Basu B; Yap TA; Molife LR; de Bono JS
    Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors.
    Gachechiladze M; Skarda J; Bouchalova K; Soltermann A; Joerger M
    Front Oncol; 2020; 10():581217. PubMed ID: 33224881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting DNA repair mechanisms in cancer.
    Furgason JM; Bahassi el M
    Pharmacol Ther; 2013 Mar; 137(3):298-308. PubMed ID: 23107892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poly-ADP ribosylation in DNA damage response and cancer therapy.
    Hou WH; Chen SH; Yu X
    Mutat Res Rev Mutat Res; 2019; 780():82-91. PubMed ID: 31395352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
    Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
    J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
    Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
    Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment.
    Maresca L; Stecca B; Carrassa L
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities.
    Jurkovicova D; Neophytou CM; Gašparović AČ; Gonçalves AC
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells.
    Takeuchi M; Tanikawa M; Nagasaka K; Oda K; Kawata Y; Oki S; Agapiti C; Sone K; Miyagawa Y; Hiraike H; Wada-Hiraike O; Kuramoto H; Ayabe T; Osuga Y; Fujii T
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31805725
    [No Abstract]   [Full Text] [Related]  

  • 31. DNA damage checkpoint kinases in cancer.
    Smith HL; Southgate H; Tweddle DA; Curtin NJ
    Expert Rev Mol Med; 2020 Jun; 22():e2. PubMed ID: 32508294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.
    Carrassa L; Colombo I; Damia G; Bertoni F
    Cancer Treat Rev; 2020 Nov; 90():102090. PubMed ID: 32892059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics.
    Arjumand W; Asiaf A; Ahmad ST
    Methods Mol Biol; 2018; 1699():3-21. PubMed ID: 29086365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP).
    Rosen DB; Leung LY; Louie B; Cordeiro JA; Conroy A; Shapira I; Fields SZ; Cesano A; Hawtin RE
    J Transl Med; 2014 Jun; 12():184. PubMed ID: 24965603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting DNA damage response kinases in cancer therapy.
    Gottifredi V
    Mutat Res; 2020; 821():111725. PubMed ID: 33157476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
    Shi C; Qin K; Lin A; Jiang A; Cheng Q; Liu Z; Zhang J; Luo P
    J Exp Clin Cancer Res; 2022 Sep; 41(1):268. PubMed ID: 36071479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. G2/M Checkpoint Abrogation With Selective Inhibitors Results in Increased Chromatid Breaks and Radiosensitization of 82-6 hTERT and RPE Human Cells.
    Nikolakopoulou A; Soni A; Habibi M; Karaiskos P; Pantelias G; Terzoudi GI; Iliakis G
    Front Public Health; 2021; 9():675095. PubMed ID: 34123995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA Damage Repair Inhibitor for Breast Cancer Treatment.
    Min A; Lee KH; Im SA
    Adv Exp Med Biol; 2021; 1187():159-179. PubMed ID: 33983578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent Advances in Therapeutic Application of DNA Damage Response Inhibitors against Cancer.
    Fernandes SG; Shah P; Khattar E
    Anticancer Agents Med Chem; 2022; 22(3):469-484. PubMed ID: 34102988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting ATR in cancer medicine.
    Sundar R; Brown J; Ingles Russo A; Yap TA
    Curr Probl Cancer; 2017; 41(4):302-315. PubMed ID: 28662958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.